Bryan Garnier - Osmozis (ALOSM.PA) OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

Report

Bryan Garnier

Thomas Coudry

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%)
Bright year ahead

Strong start of the year…
… leading to revised estimates
TP increased, investment case confirmed

14/01/2022 1 EN

Underlying

Osmozis

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Thomas Coudry

Other Reports on these Companies

Bryan Garnier

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition Solid profitability in 2020-21 Transformation of the group under way Further growth expected this year with EBITDA margin of 33% at least Buy reiterated, on the back of a positive momentum

December 15, 2021 December 15, 2021 4 EN

Bryan Garnier

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

OSMOZIS - BUY | EUR8 VS. EUR6.7 (+34%) Strong FY EBITDA margin expected after a good summer. A dynamic summer EUR2.5m of EBITDA reachable this year Solid mid-term guidance

October 13, 2021 October 13, 2021 4 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

April 25, 2025 April 25, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

April 25, 2025 April 25, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

April 25, 2025 April 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe